Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GLP-1 Receptor Agonists and Risk for Cirrhosis and Related Complications in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Fasiha Kanwal, Jennifer R. Kramer, Liang Li, et al.
JAMA Internal Medicine (2024) Vol. 184, Iss. 11, pp. 1314-1314
Closed Access | Times Cited: 24

Showing 24 citing articles:

Glucagon‐Like Peptide‐1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes
Chia‐Chih Kuo, Min‐Hsiang Chuang, Chun‐Hsien Li, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 4
Consensus Guidelines for the Diagnosis and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Adult Asian Indians with Type 2 Diabetes
Anoop Misra, Ashish Kumar, Mohammad Shafi Kuchay, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2025) Vol. 19, Iss. 3, pp. 103209-103209
Closed Access | Times Cited: 2
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2025) Vol. 187, pp. 171380-171380
Open Access | Times Cited: 1
Recent advances in incretin-based therapy for MASLD: from single to dual or triple incretin receptor agonists
Giovanni Targher, Alessandro Mantovani, Christopher D. Byrne, et al.
Gut (2024), pp. gutjnl-334023
Closed Access | Times Cited: 4
Current and emerging strategies for the prevention of hepatocellular carcinoma
Yee Hui Yeo, Manal F. Abdelmalek, Seema A. Khan, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 22, Iss. 3, pp. 173-190
Closed Access | Times Cited: 4
Authors reply: Obesity treatment in adolescents and adults in the era of personalized medicine
Magnus Sundbom, Kajsa Järvholm, Lovisa Sjögren, et al.
Journal of Internal Medicine (2025)
Closed Access
Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis
Georgiana-Diana Cazac, C.M. Lǎcǎtusu, Elena-Daniela Grigorescu, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1042-1042
Open Access
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management
Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, et al.
Exploration of Medicine (2025)
Open Access
Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment
Christopher D. Byrne, Angelo Armandi, Vanessa Pellegrinelli, et al.
Nature Reviews Gastroenterology & Hepatology (2025)
Closed Access
Role of anti-diabetic medications in the management of MASLD
Scott Isaacs, Fiona V Farrelly, Paul Brennan
Frontline Gastroenterology (2025), pp. flgastro-102856
Closed Access
Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies
Ciro Celsa, Grazia Pennisi, Adele Tulone, et al.
Gut (2025), pp. gutjnl-334591
Closed Access
Anti-obesity drugs for the gastroenterologists
Lisa Sharkey
Frontline Gastroenterology (2025), pp. flgastro-102995
Closed Access
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
Klaudia Nowak, Krzysztof Łupina, Anna Romac, et al.
Annals of Pharmacotherapy (2025)
Closed Access
MetALD: New Perspectives on an Old Overlooked Disease
Gustavo Ayares, Luis Antonio Díaz, Francisco Idalsoaga, et al.
Liver International (2025) Vol. 45, Iss. 5
Open Access
7. MANAGEMENT OF METABOLIC-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN TYPE 2 DIABETES
Stephen Colagiuri, Antonio Ceriello
Diabetes Research and Clinical Practice (2025), pp. 112151-112151
Closed Access
Antifibrotic Therapies for Metabolic Dysfunction-associated Steatotic Liver Disease
Robert F. Schwabe, Frank Tacke, Atsushi Sugimoto, et al.
JHEP Reports (2025), pp. 101421-101421
Open Access
Update in non-alcoholic fatty liver disease management: role of sodium-glucose cotransporter 2 inhibitors
Oscar René Zambrano-Vásquez, Fernando Cortés-Camacho, Jorge Ismael Castañeda‐Sánchez, et al.
Life Sciences (2025), pp. 123638-123638
Closed Access
Efficacy and Safety of Tirzepatide for Weight Management in Non-Diabetic Obese Individuals: A Narrative Review
Mohammed Sallam, Johan Snygg, Sara El Ghandour, et al.
Obesities (2025) Vol. 5, Iss. 2, pp. 26-26
Open Access
Glucagon-like-peptide 1 receptor agonist for metabolic dysfunction-associated steatotic liver disease: hype or hope?
Yu Jun Wong, George Boon‐Bee Goh
Singapore Medical Journal (2025) Vol. 66, Iss. 4, pp. 173-174
Open Access
Temporal Changes in Obesity and Outcomes for Patients Listed for Liver Transplant
Christine E. Haugen, Suhani S. Patel, Ralph C. Quillin, et al.
Journal of Gastrointestinal Surgery (2025), pp. 102071-102071
Closed Access
GLP-1 Receptor Agonists: Encouraging Signals for Treating Alcohol Use Disorder
Marlene C. Lira, Eileen Barrett, Maitreya Coffey
Journal of General Internal Medicine (2025)
Open Access
Impact of GLP- 1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia
Zoe Memel, Stephanie Gold, Michelle Pearlman, et al.
Current Nutrition Reports (2025) Vol. 14, Iss. 1
Closed Access
Nouveaux médicaments de l’obésité : quelle pertinence ?
Jacques Bringer
Bulletin de l Académie Nationale de Médecine (2025)
Closed Access
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Weixin Wang, Xin Gao, Wei Niu, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 9, pp. 4077-4077
Open Access
Risk of Hepatocellular Carcinoma with Glucagon-like Peptide-1 receptor agonist treatment in patients: a systematic review and meta-analysis
Muhammed Shabil, Mahalaqua Nazli Khatib, Suhas Ballal, et al.
BMC Endocrine Disorders (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Page 1

Scroll to top